Book chapter
AFTER-MARKET DRUG REGULATION: AN ESSENTIAL ELEMENT OF PUBLIC TRUST IN INNOVATION
Research in Human Capital and Development
01 Jan 2007
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Newly marketed drugs present unavoidable risks, no matter how diligent the level of pre-market review. Numerous adverse drug events attest to the need for post-market vigilance. However, the Food and Drug Administration monitors drugs with considerably less rigor after launch than before. This burdens both public health and public trust in the safety of new medicines. As new technologies such as genomics guide a larger share of drug development, the issue will become more acute. Most reform proposals present considerable logistical challenges. A promising alternative is to harness existing managed care databases to search for drug effects.
Metrics
Details
- Title
- AFTER-MARKET DRUG REGULATION: AN ESSENTIAL ELEMENT OF PUBLIC TRUST IN INNOVATION
- Creators
- Robert I. Field
- Contributors
- Farquhar (Editor)K H Summers (Editor)A Sorkin (Editor)
- Publication Details
- Research in Human Capital and Development
- Series
- Research in Human Capital and Development
- Publisher
- Emerald Group Publishing; BINGLEY
- Number of pages
- 25
- Resource Type
- Book chapter
- Language
- English
- Academic Unit
- Thomas R. Kline School of Law
- Web of Science ID
- WOS:000270903800002
- Scopus ID
- 2-s2.0-53849118811
- Other Identifier
- 991019298901504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Business
- Economics